Background-Pulmonary veno-occlusive disease is caused by excessive cell proliferation and fibrosis, which obliterate the lumen of pulmonary venules, leading to pulmonary hypertension, right ventricular failure, and death. This condition has no effective treatment and a 5-year survival of <5%. Understanding the mechanism of this disease and designing effective therapies are urgently needed. Methods and Results-We show that mice with homozygous deletion of the Ets transcription factor Erg die between embryonic day 16.5 and 3 months of age as a result of pulmonary veno-occlusive disease, capillary hemorrhage, and pancytopenia. We demonstrate that Erg binds to and serves as a transcriptional activator of the G-protein-coupled receptor gene Aplnr, the expression of which is uniquely specific for venous endothelium and that knockout of either Erg or Aplnr results in pulmonary venule-specific endothelial proliferation in vitro. We show that mice with either homozygous-global or endothelium-directed deletion of Aplnr manifest pulmonary veno-occlusive disease and right heart failure, detectable at 8 months of age. Levels of pulmonary ERG and APLNR in patients with pulmonary veno-occlusive disease undergoing lung transplantation were significantly lower than those of control subjects. Conclusions-Our results suggest that ERG and APLNR are essential for endothelial homeostasis in venules in the lung and that perturbation in ERG-APLNR signaling is crucial for the development of pulmonary veno-occlusive disease. We identify this pathway as a potential therapeutic target for the treatment of this incurable disease.
P ulmonary veno-occlusive disease (PVOD) is characterized by structural remodeling of postcapillary venules and small veins in the lung, resulting in intimal thickening, fibrosis, luminal occlusion, and thrombosis. This disease is unique to the venous side of the pulmonary circulation, sparing the pulmonary arterial and systemic circulations. Clinically, PVOD results in progressive elevation in pulmonary arterial pressure, leading to right heart failure and death. PVOD is distinct from pulmonary arterial hypertension, a disease characterized by small pulmonary artery occlusion. PVOD accounts for 5% to 10% of unexplained pulmonary hypertension cases, and the median survival of PVOD patients is <3 years from diagnosis. 1 There is no effective therapy for PVOD, and lung transplantation is reserved for patients with end-stage disease. Critical barriers to designing PVOD therapies are the paucity of research focusing on the venous pulmonary circulation, the lack of animal models recapitulating this disease, and the absence of tools that allow early diagnosis and the study of disease progression in humans.
Clinical Perspective on p 1191
Recently, Erg, a member of the Ets family of transcription factors, has been identified as a key modulator of endothelial cell differentiation 2 and hematopoiesis. 3 Erg, required for angioblast differentiation along the endothelial/hematopoietic lineages, is known to modulate endothelium-specific genes, including
VE-cadherin (Cdh5), von Willebrand factor (Vwf), endoglin (Eng), intercellular adhesion molecule-2 (Icam2), secreted acidic cysteine rich glycoprotein (Sparc), angiopoietin-2 (Angpt2), EGF-like domain 7(Egfl7), endothelial nitric oxide synthase (Nos3), heme oxygenase (Hmox1)
, and hairy/enhancer of split 2 (Hey2). 2 Suppression of Erg has been associated with decreased ability to form tube-like structures 4 and activation of proinflammatory genes such as interleukin 8 (Il8) and nuclear factor of kappa light polypeptide gene enhancer in B cells (Nfkb1). 5, 6 Clues as to the role of Erg in endothelium have been suggested by experiments in Xenopus. Erg expression in embryos by RNA Several lines of evidence suggest that the G protein-coupled receptor APNR functions in both the cardiac and vascular systems. Administration of apelin, the only known ligand for the Aplnr receptor, has been shown to increase cardiac contractility in animals, 8 whereas left ventricular failure in humans is associated with low levels of apelin. 9 In addition to cardiac effects, a role for Aplnr is emerging in the venous vasculature. First, in the retinal vasculature of the mouse, Aplnr has been shown to be specific for venule endothelium. 10 Second, apelin has been found to have venodilator effects in conscious rats. 11 Third, apelin has been demonstrated to be a potent mitogenic and chemotactic factor in in vivo venous angiogenesis assays involving Xenopus embryos and chicken chorioallantoic membrane. 12 Fourth, apelin or Aplnr knockdown inhibits hypoxia-induced venous regeneration in caudal fin regrowth of Fli-1 transgenic zebrafish. 13 These studies point to the concept that Aplnr signaling has direct and unique effects on the venous circulation.
With this background, we explored the role of Erg and Aplnr in the pulmonary venous circulation. We report the development of Erg-and Aplnr-null mice as the first animal models for PVOD. We demonstrate a novel role of ERG signaling in controlling venous endothelial proliferation and show a mechanistic link through ERG-dependent activation of APLNR as critical to maintaining pulmonary venous endothelial homeostasis. Our work suggests that PVOD is caused by perturbations in the ERG-APLNR signaling pathway and provides a new therapeutic target for this lethal disease, with high translational potential.
Methods
A description of routine methodologies is provided in the online-only Data Supplement.
Human Tissue Processing
Measurements of human pulmonary and systemic arterial pressures and lung biopsy were performed as previously described.
14 Tissue was collected from 15 human subjects with PVOD (pulmonary artery systolic pressure >90 mm Hg, pulmonary vascular resistance >680 dynes·s
) undergoing lung transplantation and 15 individuals without pulmonary hypertension (mean pulmonary artery pressure <20 mm Hg, pulmonary vascular resistance <220 dynes·s −1 ·cm −5 ) undergoing lung resection for benign nodules. PVOD or benign pathology was verified from explanted lung tissue by a pathologist. All subjects had given consent for lung biopsy. This study was approved by the University of California, San Diego Institutional Review Board, and experiments were performed within relevant guidelines and regulations of this body.
Generation of Erg and Aplnr Knockout Mice
Details are given in the online-only Data Supplement.
Histological and Immunohistochemical Analyses
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation was performed using the Farnham Laboratory chromatin immunoprecipitation protocol (Farnham Laboratory, Sacramento, CA). Mouse lung tissue was minced in cell lysis buffer containing protease inhibitor (Sigma, St. Louis, MO). After homogenization at 4°C, genomic DNA was sheared by sonication into 1-to 2-kb fragments. Samples were centrifuged at 14 000 rpm for 10 minutes, and the supernatant was divided evenly into 4 tubes. DNA extracted from the first aliquot was used as the total input DNA. Erg antibody (2 μg) and negative control IgG (rabbit; 2 μg) were added to the second and third aliquots, respectively, and incubated overnight at 4°C. No antibody or IgG was added to the fourth aliquot, which was used as a negative control. Aliquots 2 through 4 were incubated with protein G beads for 1.5 hours. At the end of incubation, beads were washed, and immunoprecipitated DNA was eluted and purified by reversing the cross-linking, removing the RNA, and treating with proteinase K. Extracted DNA was used as template for quantitative polymerase chain reaction using primers specific to the Aplnr promoter sequence to amplify regions containing putative ETS binding sites. Primer sequences used are described in the online-only Data Supplement.
RNA and Protein Methods
Measurement of Luciferase Activity
Isolation and Culture of Human and Mouse Pulmonary Venous Endothelial Cells and Pulmonary Artery Endothelial Cells
Endothelial Cell Growth Assays and Adenoviral Transduction
Human pulmonary venous endothelial cells (PVECs) or mouse PVECs derived from the lungs of 5 Erg −/− and 5 Erg +/+ mice were used for endothelial cell growth assays. Cells were seeded at 5×10 5 cells per 35-mmdiameter well and growth arrested 12 hours later by washing the cells 3 times with PBS before the addition of endothelial cell growth media (Cell Application, Inc) without FBS. Cells were incubated at 37°C and 5% CO 2 for 6 hours and then treated with adenovirus (pAd/CMV/ V5-DEST vector [Invitrogen] containing the cytomegalovirus [CMV] early promoter driving mouse Erg, human ERG, or mouse Aplnr [amino acid sequences for Erg and Aplnr vectors are given in the online-only Data Supplement]). Adeno-Erg, adeno-ERG, and adeno-Aplnr vectors also contained the Escherichia coli lacZ gene driven by a second CMV early promoter. Transduction efficiency was assessed by measuring the ratio of X-gal-stained cells to nonstained cells for each vector transduction. For all vectors, 12 independent viral infections per subculture were performed, with a multiplicity of infection of 100. Cell counts and 3 [H] leucine incorporation assays were performed as previously described.
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Apelin Measurements
Mouse Hemodynamic Measurements, Pulmonary Angiography, and Cardiovascular Evaluation
Animal experiments were approved by the University of California, San Diego Animal Subjects Committee and were done in accordance with the relevant guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals. We performed mouse hemodynamic measurements, pulmonary arteriography, and cardiac weight studies as previously described.
14 For retrograde pulmonary venous angiography, animals were euthanized, and a left thoracotomy with pericardiectomy was performed. The main pulmonary artery was divided, allowing free egress of blood from the pulmonary artery. The left superior pulmonary vein was cannulated with a 29-gauge needle, and the left upper lobe was perfused in situ through the left superior pulmonary vein with 3 mL Microfil, a liquid silicon-based polymer (Flow Tech, Carver, MA), for 1 minute with an infusion pump. For coronary angiography, animals were euthanized, a cross-clamp was placed on the ascending aorta, and the coronaries were perfused with 1 mL Microfil for 1 minute with an infusion pump. For pulmonary arteriography, pulmonary venography, and coronary angiography, Microfil was allowed to harden in situ for ≈1 hour. Organs were harvested, processed per the manufacturer's protocol, and photographed with a digital photomicroscope (Zeiss, Jena, Germany).
Epoprostenol Challenge and Pulmonary Vein Contraction Experiments
Echocardiographic Assessment of Cardiac Function
Statistical Analysis
Data are expressed as mean±SEM. Statistical analysis was carried out with the Kruskal-Wallis 1-way ANOVA for multiple-group analysis. When 2 groups with continuous data were compared, statistical differences were assessed with the Wilcoxon rank-sum test. All P values are 2 sided, with significance defined as P<0.01. Because of the nature of the study, there was no adjustment for multiple comparisons. The number of animals or samples in each group is indicated in the figure legends or methods.
Results
Vascular Expression of Erg and Aplnr
We studied the expression of the transcription factor ERG in human and mouse heart and lung. Immunofluorescent staining showed that ERG expression was confined to nuclei of cardiomyocytes in the outer myocardium and endothelial cells in the arteries and veins of the pulmonary and coronary circulations in humans and mice ( Figure 1A ). Because X-msr (Aplnr) had been implicated as a target of Erg in Xenopus and to facilitate visualization of Aplnr expression, we generated nuclear lacZ (nlacZ) knock-in into the endogenous Aplnr locus in mouse ( Figure I in the online-only Data Supplement). We found that Coimmunostaining with platelet endothelial cell adhesion molecule-1 (Pecam-1), neuropilin-1 (Nrp-1; artery endothelium specific), and nuclear receptor subfamily 2 group F member (Nr2f-2; known as COUPTF-II, vein endothelium-specific) antibodies confirmed that β-gal (Aplnr) expression localized to venous endothelium, whereas Erg expression localized to arterial and venous endothelium in the lungs and heart (Figure 1C-1E and Figure II in the online-only Data Supplement). We further showed that Aplnr expression is not seen in lymphatic vessels by performing coimmunostaining experiments with monoclonal antibody to podoplanin, a lymphatic endothelial marker in mice, 15 in conjunction with antibody to β-gal (Aplnr). Podoplanin expression was isolated to lymphatic vessels in mouse lung, whereas Aplnr expression was confined to veins only (data not shown).
Erg Binds to the Aplnr Promoter, Activating Aplnr Transcription in PVECs
We identified that the mouse and human Aplnr promoters (−3179 to −1) each contain 12 Erg binding sites, identified by the consensus sequence (A/G)(G/C)AGGAA(A/G). 6 Chromatin immunoprecipitation assays showed that Erg binds to the mouse Aplnr promoter, with strong affinity of Erg to the consensus site located at 248 base pairs proximal to the Aplnr transcription start site (Figure 2A and 2B).
We investigated whether ERG overexpression was associated with an increase in APLNR mRNA in vitro. Human PVECs (isolated from pulmonary veins <500 μm in diameter) and human pulmonary arterial endothelial cells (PAECs; isolated from pulmonary arteries <500 μm in diameter) infected with ERG adenovirus showed constitutive ERG protein levels compared with lacZ-transduced cells ( Figure 2C ). PVECs transduced with ERG adenovirus showed markedly higher levels of APLNR mRNA compared with PAECs transduced with the same vector and lacZ-transduced cells ( Figure 2D and 2E). Selective induction was seen for APLNR expression in PVECs and not for other genes known to be transcriptionally activated by ERG, including CDH5, HMOX1, HEY2, and ICAM2 ( Figure 2F ). Using a dual-luciferase reporter assay, we found strong activation of APLNR transcription in the presence of ERG in human PVECs but not in human PAECs ( Figure 2G ). Progressive deletion of the promoter region of APLNR in luciferase assays demonstrated that region −600 to −200 was necessary for promoter activity in the presence of ERG in PVECs ( Figure 2H ). These results suggest that ERG regulates APLNR expression through a promoter-dependent mechanism in pulmonary venous endothelium.
High-level ERG expression in human PVECs conferred a significantly decreased growth rate at preconfluence and decreased proliferation as determined by 3 [H]leucine incorporation ( Figure 2I ). Constitutive ERG expression in PAECs did not affect growth rate or proliferation ( Figure 2I ). Apelin12 levels in culture supernatants were equal in ERG-and lacZ-transduced PVECs and PAECs (ERG-transduced PVECs, 0.07±0.04 ng/mL; lacZ-transduced PVECs, 0.09±0.05 ng/mL; ERG-transduced PAECs, 0.07±0.06 ng/mL; ERG-transduced PAECs, 0.08±0.05 ng/mL). There was no difference in apelin protein levels in human PVECs and PAECs transduced with either ERG or lacZ by Western blotting.
Decreased ERG and APLNR Correlate With PVOD Phenotype in Humans
We examined the expression pattern of ERG and APLNR in the lungs of 15 patients with PVOD and compared them with lung biopsies from 15 individuals without pulmonary hypertension. We found significantly decreased levels of ERG protein ( Figure 3A) and APLNR mRNA and protein ( Figure 3B and 3C) in human PVOD lung tissue compared with that of normotensive control subjects. In contrast, we found no difference in the levels of other genes controlled by ERG (CDH5, NOS3, HMOX1, HEY2, and ICAM2) in PVOD specimens compared with control subjects ( Figure 3D ). These results suggest that attenuation of ERG and APLNR correlates with the PVOD disease phenotype in humans. Figure 4A ), immunostaining with antibody to Nr2f-2, and lack of immunostaining with antibody to Nrp-1 verified that occluded vessels were venules ( Figure 4C ). Cells blocking venule lumina in the pulmonary circulation stained positive for Pecam-1 but not Acta-2, indicating endothelial phenotype ( Figure 4C ). Small pulmonary arteries were histologically normal ( Figure 4A ). Morphometric studies of lungs from Erg −/− mice were performed to assess evidence of postcapillary venule remodeling. Pulmonary venule occlusion was widespread in Erg-null mice and was not seen in littermate controls (Table II in Figure 4D ). Venous angiograms of Erg −/− mice were markedly abnormal with small-vessel pruning and absence of peripheral vascular blush, whereas pulmonary arteriograms were normal appearing ( Figure 4E ). We confirmed the presence of pulmonary hypertension from venous obstruction in Erg −/− mice that survived past 4 weeks by measurement of RV hypertrophy. The ratio of RV weight to that of the left ventricle and septum was significantly increased in 4-week-old Erg −/− mice compared to that seen in heterozygous and wild-type littermates ( Figure 4F ). Erg −/− mice challenged with the pulmonary vasodilator epoprostenol developed life-threatening pulmonary edema, similar to the response to this drug in humans with PVOD ( Figure 4G ). Vasodilatorinduced pulmonary edema in humans with PVOD results from vasodilation of the precapillary vessels more so than postcapillary vessels, leading to increases in transcapillary hydrostatic pressure and fluid transudation into alveolar spaces. 16 To test whether RV failure was due to PVOD rather than coronary defects, we performed coronary arteriography and venous photography in Erg −/− mice and littermates. No difference was noted in coronary artery/vein configuration or luminal 
Erg
Erg Inhibits Proliferation of PVECs Through Aplnr
Because endothelial proliferation is a mechanism of vascular remodeling in PVOD, we investigated whether homozygous deletion of Erg affected PVEC proliferation through modulation of Aplnr. First, we found that within Erg −/− mouse lungs, there were undetectable Aplnr mRNA levels ( Figure 5A ). Erg −/− PVECs had markedly diminished expression Aplnr mRNA compared with wild-type PVECs ( Figure 5B) . Second, growth rates of Erg −/− and Aplnr −/− PVECs were compared with those of wild-type PVECs. Knockout of Erg ( Figure 5C ) or Aplnr ( Figure 5D ) in PVECs resulted in significantly increased growth rates at preconfluence and increased proliferation, as determined by 3 [H]leucine incorporation, compared with wild-type PVECs. In contrast, knockout of Erg ( Figure 5C ) or Aplnr ( Figure 5D ) in PAECs had no measurable effect on PAEC growth rate, proliferation, or 3 [H]leucine incorporation. These data suggested that the normal function of the Erg-Aplnr axis in PVECs is to limit proliferation and to maintain cellular quiescence. We performed rescue experiments to determine whether repletion of Erg or Aplnr in Erg −/− PVECs would attenuate PVEC proliferation. Constitutive expression of Erg in Erg −/− PVECs restored high levels of Aplnr expression ( Figure 5E ) and decreased cellular proliferation and :nlacZ mice showed normal pulmonary arterial anatomy, distribution, and patency; however, pulmonary venules (<250 μm in diameter) in all lobes manifested narrowing and occlusion, similar to the phenotype seen in Erg −/− mice ( Figure 6B ). Cells blocking venule lumina stained positive for Pecam-1 and Nr2f-2 and negative for Nrp-1 and Acta-2, indicating a venous endothelial phenotype ( Figure 6C ). Pulmonary hemorrhage was not seen. Proliferating cell nuclear antigen expression was higher in small venules in Aplnr-null mice compared with littermates at 8 months ( Figure 6B ). Quantification revealed that >60% :nlacZ-Flk-1Cre mice, whereas vessel/alveoli ratios were similar between knockout and control mice at 10 months (Table IV in mice with epoprostenol induced the development of severe pulmonary edema, similar to the response to this drug in Erg −/− mice ( Figure 6F) .
On the basis of data suggesting that apelin may function as a systemic venodilator in rats, 11 we examined whether pulmonary hypertension in Aplnr-null mice could be attributed to alterations in pulmonary venous myogenic tone. We compared agonist-mediated vasoconstriction of isolated intrapulmonary small veins from Aplnr :nlacZ mice ( Figure  IV in the online-only Data Supplement). We also tested whether there is a venodilator effect of apelin on pulmonary vessels in wild-type mice. We found that 0.1 to 100 μmol/L apelin had no effect on active tension induced by phenylephrine in pulmonary vein rings derived from wild-type mice, suggesting differences in the effect of apelin on systemic and pulmonary circulations ( Figure Figure 6G ). Collectively, these data suggest that Aplnr knockout did not have a direct effect on myocardial function and that the development of RV hypertrophy correlated with development of PVOD and pulmonary hypertension.
Discussion
The identification of pathways that regulate venous endothelium and the possibility of manipulating such pathways in vivo have potential therapeutic applications. This study identifies ERG and APLNR as crucial mediators of PVEC proliferation and crucial mediators for the development of rodent PVOD and possibly human PVOD.
Our goal has been to understand the molecular causes of different types of human pulmonary hypertension and, in doing so, to shed light on the fundamental differences between arteries and veins. From the work presented, we have 4 major conclusions. First, we show that Aplnr is specific for venous endothelium in multiple organs in both mice and humans. This result underscores that the physiological and pathological distinctions between arteries and veins are not due simply to differences in anatomy, oxygenation, or blood pressure but are related to a specific genetic difference. Second, we show that the transcription factor ERG regulates vein-specific APLNR expression in mice and humans. In previous studies, Erg has been necessary for selfrenewing hematopoiesis and marrow angioblast differentiation in the embryo. 17 Our findings of PVOD and pancytopenia in Erg −/− mice raise the question of whether venous specificity through the Erg-Aplnr axis may occur before separation of hematopoietic and endothelial lineages. Third, we find that the anatomic consequence of Erg or Aplnr knockout is the development of PVOD, with small pulmonary venule occlusion secondary to excessive endothelial proliferation. This finding, coupled with the observation that ERG and APLNR are markedly diminished in lungs of individuals with PVOD, supports a role of ERG and APLNR in modulating venous endothelial homeostasis within the pulmonary vasculature. Although vasodilator effects have been reported for apelin in the systemic circulation, 11 we found no evidence that Aplnr knockout affects vasoreactivity of the pulmonary circulation. Similar to our data, others have shown that administration of apelin to normal anesthetized dogs has no effect on the mean pulmonary artery pressure. 18 Fourth, we demonstrate that the absence of Erg expression in venous endothelium confers a proliferative capacity on PVECs and that restoration of either Erg or Aplnr expression attenuates proliferation of venous endothelial cells in vitro. Collectively, these results suggest that the normal function of the Erg-Aplnr axis is to suppress venous endothelial proliferation and to maintain cellular quiescence within the adult lung.
Human PVOD has no known cure except lung transplantation. To date, the processes that contribute to intimal hyperplasia and fibrosclerosis seen in venules and small veins within the lung of PVOD patients are unknown, although by pathological and immunohistochemical analysis, neointimal cells seen in PVOD have characteristics and biomarkers of endothelium. 19 We have chosen to focus on endothelial proliferation as a potential contributor to disease phenotype, although we recognize that other mechanisms such as acute inflammation, perivenular fibrosis, and cellular migration or transdifferentiation within the wall of pulmonary veins may also play a role.
Human PVOD may occur as an isolated entity or in conjunction with pulmonary capillary hemangiomatosis (PCH), a condition characterized by abundant well-circumscribed areas of capillary proliferation that expand alveolar septa and often invade bronchial walls and pleura. 19 To date, it is unknown whether PVOD and PCH are distinct disorders or different overlapping manifestations of the same disorder. Our Erg −/− and Aplnr −/− mice that develop PVOD do not manifest PCH pathology and thus represent animal models for study of pure postcapillary venous obstructive pathology.
Clues as to why ERG may have a role in the vessel narrowing/occlusion seen in PVOD may be analyzed from studies examining vessel caliber and lumen patency in zebrafish, Xenopus, and mice. Others have demonstrated Erg expression in areas of capillary-venous sprouting in utero and venules in the adult frog. 10, 12 Erg has also been shown to control the expression of Egfl7, a secreted protein that regulates lumen formation in blood vessels in zebrafish 20 and inhibits Notch activity in murine endothelium. 21 Notch negatively regulates endothelial proliferation, where it inhibits endothelial cell sprouting responses. Loss of Egfl7 in zebrafish blocks vascular tubulogenesis and attenuates luminal patency. 20 Thus, it is possible that Erg limits proliferation of venous endothelium not only through transcriptional upregulation of Aplnr but also through the modulation of Egfl7 or Notch. The fact that Erg −/− mice develop pancytopenia and manifest lung hemorrhage with a more severe, earlier-onset phenotype of PVOD than Aplnr −/− mice suggests that Erg may have effects on multiple pathways. Pulmonary capillary hemorrhage in Erg −/− PVOD mice correlates with earlier work showing that Erg is a positive regulator of Cdh5 and Icam2, 4 both genes encoding proteins that promote endothelial integrity. Occult pulmonary hemorrhage occurs often in humans displaying PVOD, previously thought to be due solely to postcapillary block. September 30, 2014
In support of a role for Aplnr in vascular homeostasis, we provide evidence that Aplnr signaling is crucial for maintaining the correct endothelial cell number that maintains luminal patency of venules in the lung. Our work contrasts with findings from others that suggest that apelin has effects in the adult rodent arterial circulation (where Aplnr is not expressed), including vasodilation, 22 aneurysm formation, 23 atherosclerosis enhancement, 23 and protection against pulmonary arterial hypertension. 24 The clear-cut specificity of Aplnr for veins suggests that the reported effects of apelin in arteries may be due to interaction with a different receptor from Aplnr.
Currently, apelin is the only known ligand for Aplnr, and Aplnr is considered to be the only receptor for apelin. However, it is important to note that the phenotype of Aplnr −/− mice is different from that of apelin −/− mice. 25 Similarly, developmental work in zebrafish has suggested that the loss of apelin does not phenocopy the loss of Aplnr (agtrl 1b). 26 The differences between apelin-and Aplnrnull mice, particularly with respect to pulmonary arterial hypertension and PVOD, may reflect other unknown ligands or receptors or ligand-independent functions of Aplnr such as heterodimerization with other G protein-coupled receptors. Supporting this concept is the observation that Aplnr and the G protein-coupled receptor angiotensin II type 1A receptor have been found to physically associate intracellularly under certain conditions. 23 Our work underscores the concept that receptors and transcription factors may play different roles in different tissues. Previous studies have focused on the effects of apelin levels on cardiac contractility, with increased cardiac levels seen in RV hypertrophy and reduced levels seen in RV failure. 27 Although we find that in addition to venous endothelial expression, Aplnr is found in RV and left ventricular cardiomyocytes, we have been unable to demonstrate any difference in left ventricular myocardial contractility between global and endothelium-directed Aplnr-null mice and control littermates. We have found that ventricular size and function are normal in Aplnr −/− :nlacZ and Aplnr f/f :nlacZFlk-1Cre mice and that secondary RV hypertrophy and failure occur only after the development of PVOD. Taken together with our data, the observation that apelin may improve RV function in experimental models of pulmonary arterial hypertension 28 suggests that either Aplnr signaling may improve pulmonary venous patency with consequent improvement in RV unloading or apelin may have direct effects on the failing RV. We cannot exclude the possibility that RV failure in our Aplnr Finally, it has been suggested that PVOD is both a proliferative and inflammatory-fibrotic vasculopathy. The lung phenotype observed in Erg and Aplnr knockout mice demonstrates that intimal proliferation is a key component of pulmonary venule obstruction in these models of disease. Erg has also been found to have anti-inflammatory effects in endothelial cells in vitro through the repression of the Il8 gene and inhibition of the tumor necrosis factor-α-dependent activation of Nfkb1. 5, 6 Further studies are necessary to assess whether diminished levels of Erg-Aplnr signaling seen in mouse and human PVOD affect inflammation and development in this vascular bed also.
Conclusions
Our work shows that diminished or absent steady-state levels of ERG and APLNR are associated with the development of PVOD in humans and mice. Our results suggest that control of endothelial proliferation in postcapillary venules by Erg and Aplnr is a key process in venous endothelium homeostasis and may have important implications for the understanding of venous endothelial identity and the treatment of PVOD. Our work underscores the concept that the endothelium of the pulmonary venous circulation is functionally and genetically distinct from the pulmonary arterial circulation and provides a framework for testing therapies for one of the most lethal diseases known to human. Augmentation of the expression or function of this pathway in the pulmonary vasculature may be a useful strategy to treat PVOD in humans.
Addendum
Since the submission of this manuscript, 1 group has reported that mutations in the gene EIF2AK4 are associated with the development of familial PVOD and one quarter of nonfamilial PVOD cases, 29 and another group has reported that mutations in the same gene are associated with the development of familial PCH and one fifth of nonfamilial PCH cases. 30 We subsequently examined the expression of Eif2ak4 in the lungs of our 2 animal models for PVOD. We found no difference in the expression of Eif2ak4 in lung tissue from animals with homozygous or heterozygous deletion of Erg or Aplnr compared with the lungs of wildtype littermates by quantitative reverse transcription-polymerase chain reaction ( Figure VI in the online-only Data Supplement). Further studies are needed to explore the role of Eif2ak4, a kinase known to phosphorylate the α subunit of the eukaryotic translation initiation factor 2, 31 with respect to Erg/Aplnr signaling.
Sources of Funding
This work was supported by grants from the National Institutes of Health/National Heart, Lung, and Blood Institute (2R01HL70852 to Dr Thistlethwaite and 1P01 HL098053 to multiple investigators, including Dr Thistlethwaite).
Disclosures
None.
